Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMDS nasdaq bulletin board -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (3415)	5/24/1999 12:10:00 PM
From: Labrador	Read Replies (1) \| Respond to of 4122

I would rather see the trials proceed, notwithstanding the conditions. Paying up front should be no big deal, especially considering the financial condition of IMDS (i.e., no cash) -- this seem like prudent business on the part of the facility. No publicity -- isn't this what IMDS wanted in the past -- in fact, didn't they refuse to disclosure locations to avoid problems. Independent selection of patients and restricting the results until the testing is complete would provide creditability to the testing and avoid any consideration of alteration of results -- total independence. A blind study would surely add needed creditability to the testing. It seems prudent on the part of the facility. The downside to IMDS and its shareholders is continued delays in the testing of the scanners -- continued use of working capital, etc. Hope that they reconsider.